drugset / Trial / NCT05188664

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

NCT05188664

Phase 1/2 Completed 20 enrolled LaNova Medicines Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination with Toripalimab in Patients with Advanced Solid Tumors

Timeline

Start
2022-05-10
Primary completion
2023-11-14
Completion
2023-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject TPX4589 Other / unclassified Intravenous
Subject Toripalimab Monoclonal antibody Intravenous

Indications